Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism
Open Access
Abstract
Metabolic rewiring in tumor cells is a major hallmark of oncogenesis. Some of the oncometabolites drive suppressive and tolerogenic signals from the immune system, which becomes complicit to the advent and the survival of neoplasia. Tryptophan (TRP) catabolism through the kynurenine (KYN) pathway was reported to play immunosuppressive actions across many types of cancer. Extensive debate of whether the culprit of immunosuppression was the depletion of TRP or rather KYN accumulation in the tumor microenvironment has been ongoing for years. Results from clinical trials assessing the benefit of inhibiting key limiting enzymes of this pathway such as indoleamine 2,3-dioxygenase (IDO1) or tryptophan 2,3-dioxygenase (TDO2) failed to meet the expectations. Bearing in mind the complexity of the tumoral terrain and the existence of different cancers with IDO1/TDO2 expressing and non-expressing tumoral cells, here we present a comprehensive analysis of the TRP global metabolic hub and the driving potential of the process of oncogenesis with the main focus on liver cancers.Keywords
Funding Information
- Cancéropôle, Grand Sud-D Ouest, France (2020-E06)
- Association les Récoltes de l’Espoir (RE-2021-1AD-F)
- Association Cassandra contre les Leucémies et Cancers Pédiatriques (OPE-2018-0144)
This publication has 73 references indexed in Scilit:
- Toll-Like Receptor 3 and Suppressor of Cytokine Signaling Proteins Regulate CXCR4 and CXCR7 Expression in Bone Marrow-Derived Human Multipotent Stromal CellsPLOS ONE, 2012
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenaseProceedings of the National Academy of Sciences, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer CellsPLOS ONE, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory SignalingToxicological Sciences, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell CarcinomaClinical Cancer Research, 2007
- Indoleamine 2,3-dioxygenase and tumor-induced toleranceJournal of Clinical Investigation, 2007
- Epidemiology of Primary Hepatic Malignancies in U.S. ChildrenHepatology, 2003